Form 4: BioXcel CFO Converts RSUs to Common Stock

BioXcel Therapeutics' Chief Financial Officer, Richard I. Steinhart, converted a total of 68 Restricted Stock Units into common stock on March 14 and 15, 2026.

Summary

• Richard I. Steinhart, Chief Financial Officer of BioXcel Therapeutics, Inc. (BTAI), reported changes in his beneficial ownership of the company's securities.
• On March 14, 2026, 33 Restricted Stock Units (RSUs) were converted into shares of common stock.
• On March 15, 2026, an additional 35 Restricted Stock Units (RSUs) were converted into shares of common stock.
• Each RSU represents a contingent right to receive one share of BioXcel Therapeutics' Common Stock.
• The RSUs converted on March 14, 2026, are part of a grant of 521 RSUs awarded on March 14, 2022, which vest over time.
• The RSUs converted on March 15, 2026, are part of a grant of 562 RSUs awarded on March 15, 2023, which also vest over time.
• Following these transactions, Richard I. Steinhart directly beneficially owns 6,645 shares of BioXcel Therapeutics common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents the routine vesting and conversion of executive equity compensation, aligning management's interests with shareholders without indicating new operational developments.

Positives

• The conversion of Restricted Stock Units (RSUs) into common stock indicates the vesting of previously granted equity awards, which aligns management's interests with those of shareholders.
• The Chief Financial Officer's continued beneficial ownership of 6,645 shares of common stock demonstrates an ongoing equity stake in the company.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that RSU conversions are a routine part of executive compensation in the biotechnology and pharmaceutical industries, reflecting the vesting schedules designed to retain key talent and align their long-term interests with company performance. This is a standard mechanism for executives to realize value from their equity awards.

Comparison to Industry Standards

• The vesting schedule of 25% on the first anniversary and 6.25% quarterly thereafter is a common practice for executive equity compensation in the biotech sector, similar to structures seen at companies like Moderna (MRNA) or Pfizer (PFE) for their executive RSU grants, aiming for long-term retention.
• The conversion of RSUs into common stock by a Chief Financial Officer is a standard event, comparable to similar transactions reported by CFOs at peer companies such as Sarepta Therapeutics (SRPT) or Alnylam Pharmaceuticals (ALNY), indicating the realization of earned compensation.

Stakeholder Impact

• Shareholders: The conversion of RSUs into common stock slightly increases the number of outstanding shares, potentially leading to minor dilution, but also signals management's continued equity stake.
• Employees: The vesting of RSUs reinforces the company's commitment to its equity compensation plans, which can positively impact employee morale and retention, particularly for executives.

Key Dates

Recommendation

This Form 4 filing details routine RSU conversions by a company executive, which is a standard part of compensation and does not provide new material information about the company's operational performance, financial health, or strategic direction. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

BioXcel Therapeutics, BTAI, Richard Steinhart, CFO, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Equity Compensation, Beneficial Ownership